What is a notable adverse effect specifically associated with imatinib?

What is a notable adverse effect specifically associated with imatinib?

• A. Peripheral neuropathy
• B. Fluid retention
• C. Bone marrow suppression
• D. Increased liver enzymes

Answer: (B)

Fluid retention is a notable adverse effect specifically associated with imatinib, a tyrosine kinase inhibitor primarily used to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). This side effect presents as edema or swelling, which can manifest in various parts of the body, including the face and extremities. It is essential to monitor patients for signs of fluid retention, as it may lead to complications such as congestive heart failure in susceptible individuals. The mechanism behind fluid retention in patients taking imatinib is related to its inhibition of certain signaling pathways that regulate fluid balance and vascular permeability. Managing this adverse effect often involves the use of diuretics or adjustments to the patient's treatment regimen, depending on the severity of the retention. While peripheral neuropathy, bone marrow suppression, and increased liver enzymes can occur with other medications or treatment regimens, they are not specifically characteristic of imatinib. Each of those conditions can arise from different mechanisms and with various medications; thus, fluid retention is most closely associated with imatinib use.

Fluid retention is a notable adverse effect specifically associated with imatinib, a tyrosine kinase inhibitor primarily used to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). This side effect presents as edema or swelling, which can manifest in various parts of the body, including the face and extremities. It is essential to monitor patients for signs of fluid retention, as it may lead to complications such as congestive heart failure in susceptible individuals.

The mechanism behind fluid retention in patients taking imatinib is related to its inhibition of certain signaling pathways that regulate fluid balance and vascular permeability. Managing this adverse effect often involves the use of diuretics or adjustments to the patient's treatment regimen, depending on the severity of the retention.

While peripheral neuropathy, bone marrow suppression, and increased liver enzymes can occur with other medications or treatment regimens, they are not specifically characteristic of imatinib. Each of those conditions can arise from different mechanisms and with various medications; thus, fluid retention is most closely associated with imatinib use.